Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.41 |
| ▸ | AKT1 | P31749 | 3/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359396 | 0.94 | AAK1 (0.40) | AAK1CACNA1BSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3199662 | 0.84 | AAK1 (0.41) | AAK1SMYD3 | |
| SCHEMBL14920771 | 0.79 | KDM4D (0.47) | AAK1CACNA1BTRPA1KDM4DKDM4E | |
| SCHEMBL14920778 | 0.79 | KDM4D (0.47) | AAK1CACNA1BTRPA1KDM4DKDM4E | |
| SCHEMBL359262 | 0.79 | AAK1 (0.42) | AAK1SMYD3 | |
| SCHEMBL14920769 | 0.79 | KDM4D (0.47) | AAK1CACNA1BTRPA1KDM4DKDM4E | |
| SCHEMBL5653707 | 0.78 | SMYD3 (0.44) | AAK1AKT1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL358894 | 0.77 | AAK1 (0.41) | AAK1AKT1ALDH1A1ALOX12SMYD3 | |
| SCHEMBL358343 | 0.75 | SMYD3 (0.40) | AAK1AKT1SMYD3 | |
| SCHEMBL4116055 | 0.75 | SMYD3 (0.53) | AKT1ALDH1A1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003219-A | Pyrazolo [1,5A] pyrimidine and thieno [3,2B] pyrimidine derivatives as IRAK4 regulator | 弗·哈夫曼-拉罗切有限公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-105367577-B | Pyrazolo [1,5A] pyrimidine and thieno [3,2B] pyrimidine derivatives as IRAK4 regulator | 弗·哈夫曼-拉罗切有限公司 | 2019-04-23 | — | — | CN | disclosed |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | disclosed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3252054-A1 | PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-2593457-B1 | PYRAZOLO[1,5A]PYRIMIDINE AND THIENO[3,2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2017-08-23 | — | — | EP | disclosed |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. | 2016-07-21 | — | — | US | disclosed |
| US-9255110-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | ROCHE PALO ALTO LLC (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | AAK1 402/4885AKT1 1888/4885CACNA1B 4491/4885 |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | AAK1 402/4885AKT1 1888/4885CACNA1B 4491/4885 |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | AAK1 402/4885AKT1 1888/4885CACNA1B 4491/4885 |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | AAK1 402/4885AKT1 1888/4885CACNA1B 4491/4885 |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | IRAK4, IRAK1, IRAK2 | AAK1 402/4885AKT1 1888/4885CACNA1B 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.